CARMEL, Ind., May 9, 2024 /PRNewswire/ -- Syra Health Corp. (NASDAQ: SYRA), ("Syra Health" or the "Company") a healthcare technology company with a mission to improve healthcare by providing innovative services and technology solutions, announced today its financial results for the first quarter ended March 31, 2024.
Q1 2024 Financial Highlights
2024 Financial Outlook
The Company anticipates full-year 2024 revenue of $9 to $11 million, representing growth of 64%-100% versus 2023. Due to the implementation cycle of customers, the Company expects the majority of its contract revenues to be realized in the second half of 2024.
Recent Operational Highlights
Management Commentary
Dr. Deepika Vuppalanchi, CEO of Syra Health, said "We are proud of our impressive growth in 2024, as our revenues in the first quarter grew 47% versus last year. As such, we are confident in our 2024 revenue guidance of $9 million to $11 million, based on contracts in hand and pending implementation. The demand for our services remains strong and we believe we are properly positioned to take advantage. We are currently doing business in 19 states, and we anticipate securing new business from both the private and public sectors. We are excited about our Population Health business unit, which grew over 200% in the first quarter, driven by strong demand for our epidemiology services. Our growth remains strong in our newest business units of Digital Health and Health Education, and we are excited that our Healthcare Workforce business unit has returned to growth in 2024. Syrenity, our mental and behavioral health platform, which is focused on prevention, also holds great promise in terms of revenue for 2024 and beyond. We believe we are at the early stages of accelerating growth, which has been made possible by recent investments in our people and our technology."
Q1 2024 Financial Results
Revenue for the quarter ended March 31, 2024, was $1.7 million, compared to the $1.2 million reported in the first quarter of 2023. Strong growth was driven by Population Health which grew 212% year over year, and Healthcare Workforce, which grew 28% year over year. Digital Health had revenues of $92,250, compared to zero last year.
Gross profit margin in the first quarter of 2024 was 10.2%, compared to 12.4% in the first quarter of 2023. The decrease in gross margins was due to the mix shift to Healthcare Workforce.
Total operating expenses for the first quarter of 2024 were $1.6 million compared to $921,781 in the first quarter of 2023. Salaries and benefits expenses increased 61% to support general business growth and sales. Professional fees declined 18% due to decreased legal and other professional costs as the Company completed its IPO process in the fourth quarter of 2023. Selling, general and administrative expenses increased 87% due to increased operations. Depreciation expense was $12,545 compared to $11,763 in the first quarter of 2023, reflecting expanded office space. R&D expenses were $277,548, reflecting the development of technology-based solutions.
Net Loss for the third quarter of 2024 was $(1.4 million) compared to $(785,892) in the first quarter of 2023.
Adjusted EBITDA for the first quarter 2024 was $(1.4 million) compared to $(762,710) in the first quarter 2023.
Cash on hand on March 31, 2024, was $3.2 million.
Conference Call
Management will hold a conference call to discuss the fiscal year's financial results at 9:00 am ET on May 9, 2024.
Interested parties can listen via a live webcast, from the link available in the Investor Relations section of the Company's website at https://ir.syrahealth.com/presentations/q1-2024-earnings-call
A replay will be available after the call, in the Investor Relations section of the Company's website at https://ir.syrahealth.com/presentations/q1-2024-earnings-call.
Non-GAAP Financial Measures
In addition to financial results reported in accordance with accounting principles generally accepted in the United States of America ("GAAP"), we have provided the following non-GAAP financial measure in this release and the accompanying tables: adjusted EBITDA. We use this non-GAAP financial measures internally to facilitate period-to-period comparisons and analysis of our operating performance and liquidity, and believe it is useful to investors as a supplement to GAAP measures in analyzing, trending, and benchmarking the performance and value of our business. However, this measure is not intended to be a substitute for those reported in accordance with GAAP. These measures may be different from non-GAAP financial measures used by other companies, even when similar terms are used to identify such measures. For reconciliations of historical non-GAAP financial measures to the most comparable financial measures under GAAP, see the table below.
SYRA HEALTH CORP. | |||
RECONCILIATION OF ADJUSTED EBITDA TO NET LOSS | |||
Three Months Ended | |||
March 31, 2024 | March 31, 2023 | ||
Net Loss | $(1,447,050) | $(785,892) | |
Interest | 4,077 | 11,419 | |
Depreciation | 12,545 | 11,763 | |
Taxes | - | - | |
EBITDA | $(1,430,428) | $(762,710) | |
ABOUT SYRA HEALTH
Syra Health is a healthcare technology company addressing some of healthcare's most significant challenges in areas such as behavioral and mental health, digital health, and population health, by providing innovative services and technology solutions. Syra Health's products and services are centered on prevention, improved access, and affordable care. Syra Health supplies its solutions to payers, providers, life sciences organizations, academic institutions, and government. For more information, please visit www.syrahealth.com.
Forward-Looking Statements
Statements in this press release about future expectations, plans, and prospects, as well as any other statements regarding matters that are not historical facts, may constitute "forward-looking statements." These statements include, but are not limited to, statements relating to the expected use of proceeds, the Company's operations and business strategy and the Company's expected financial results. The words "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "plan," "potential," "predict," "project," "should," "target," "will," "would" and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. The forward-looking statements contained in this press release are based on management's current expectations and are subject to substantial risks, uncertainty and changes in circumstances. Investors should read the risk factors set forth in our Form 10-K for the year ended December 31, 2023, and other periodic reports filed with the Securities and Exchange Commission. Any forward-looking statements contained in this press release speak only as of the date hereof, and, except as required by federal securities laws, the Company specifically disclaims any obligation to update any forward-looking statements, whether as a result of new information, future events, or otherwise.
For more information, please contact:
Media:
Syra Health
Communications & Marketing Director
Christine Drury
317-385-9227
This email address is being protected from spambots. You need JavaScript enabled to view it.
Investors:
Ben Shamsian
Vice President
Lytham Partners, LLC
646-829-9701
This email address is being protected from spambots. You need JavaScript enabled to view it.
SYRA HEALTH CORP. | ||||||||
CONDENSED BALANCE SHEETS | ||||||||
(UNAUDITED) | ||||||||
March 31, | December 31, | |||||||
2024 | 2023 | |||||||
ASSETS | (Unaudited) | |||||||
Current assets: | ||||||||
Cash | $ | 3,237,957 | $ | 3,280,075 | ||||
Accounts receivable, net | 745,683 | 1,060,634 | ||||||
Accounts receivable related party | 82,124 | 50,614 | ||||||
Other current assets | 381,887 | 389,787 | ||||||
Total current assets | 4,447,651 | 4,781,110 | ||||||
Property and equipment, net | 72,048 | 78,974 | ||||||
Right-of-use asset | 31,826 | 63,199 | ||||||
Total assets | $ | 4,551,525 | $ | 4,923,283 | ||||
LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT) | ||||||||
Current liabilities: | ||||||||
Accounts payable | $ | 645,567 | $ | 462,991 | ||||
Accrued expenses | 319,698 | 198,978 | ||||||
Deferred revenue | 6,108 | - | ||||||
Current portion of operating lease liability, related party | 31,826 | 63,199 | ||||||
Notes payable | 99,021 | 184,904 | ||||||
Total current liabilities | 1,102,220 | 910,072 | ||||||
Total liabilities | 1,102,220 | 910,072 | ||||||
Commitments and contingencies | ||||||||
Stockholders' equity (deficit): | ||||||||
Preferred stock, $0.001 par value, 10,000,000 shares | - | - | ||||||
Class A common stock, $0.001 par value, 100,000,000 shares | 5,769 | 5,588 | ||||||
Convertible class B common stock, $0.001 par value, 5,000,000 | 833 | 833 | ||||||
Additional paid-in capital | 9,954,708 | 9,071,745 | ||||||
Accumulated deficit | (6,512,005) | (5,064,955) | ||||||
Total stockholders' equity (deficit) | 3,449,305 | 4,013,211 | ||||||
Total liabilities and stockholders' equity (deficit) | $ | 4,551,525 | $ | 4,923,283 | ||||
SYRA HEALTH CORP. | ||||||||
CONDENSED STATEMENTS OF OPERATIONS | ||||||||
(UNAUDITED) | ||||||||
For the Three Months Ended | ||||||||
March 31, | ||||||||
2024 | 2023 | |||||||
Net revenues | $ | 1,752,340 | $ | 1,188,351 | ||||
Cost of services | 1,573,053 | 1,041,195 | ||||||
Gross profit | 179,287 | 147,156 | ||||||
Operating expenses: | ||||||||
Salaries and benefits | 736,303 | 457,745 | ||||||
Professional services | 194,580 | 236,660 | ||||||
Research and development expenses | 277,548 | - | ||||||
Selling, general and administrative expenses | 402,265 | 215,463 | ||||||
Depreciation | 12,545 | 11,763 | ||||||
Total operating expenses | 1,623,241 | 921,631 | ||||||
Operating loss | (1,443,954) | (774,475) | ||||||
Other income (expense): | ||||||||
Interest income | 981 | 2 | ||||||
Interest expense | (4,077) | (11,419) | ||||||
Total other income (expense) | (3,096) | (11,417) | ||||||
Net loss | $ | (1,447,050) | $ | (785,892) | ||||
Weighted average common shares outstanding - basic and diluted | 6,495,213 | 4,353,717 | ||||||
Net loss per common share - basic and diluted | $ | (0.22) | $ | (0.18) | ||||
SYRA HEALTH CORP. | ||||||||
CONDENSED STATEMENTS OF CASH FLOWS | ||||||||
(UNAUDITED) | ||||||||
For the Three Months Ended | ||||||||
March 31, | ||||||||
2024 | 2023 | |||||||
CASH FLOWS FROM OPERATING ACTIVITIES | ||||||||
Net loss | $ | (1,447,050) | $ | (785,892) | ||||
Adjustments to reconcile net loss to net cash used in operating activities: | ||||||||
Depreciation | 12,545 | 11,763 | ||||||
Common stock issued for services | 18,875 | - | ||||||
Non-cash lease expense | 31,373 | 29,624 | ||||||
Stock-based compensation, stock options | 14,140 | 1,367 | ||||||
Changes in operating assets and liabilities: | ||||||||
Accounts receivable | 314,951 | 835,456 | ||||||
Accounts receivable, related party | (31,510) | - | ||||||
Other current assets | 7,900 | (103,025) | ||||||
Accounts payable | 182,576 | 31,775 | ||||||
Accounts payable, related parties | - | (1,600) | ||||||
Deferred revenue | 6,108 | - | ||||||
Accrued expenses | 120,720 | (34,906) | ||||||
Operating lease liability | (31,373) | (29,624) | ||||||
Net cash used in operating activities | (800,745) | (45,062) | ||||||
CASH FLOWS FROM INVESTING ACTIVITIES | ||||||||
Purchase of property and equipment | (5,619) | (9,659) | ||||||
Net cash used in investing activities | (5,619) | (9,659) | ||||||
CASH FLOWS FROM FINANCING ACTIVITIES | ||||||||
Proceeds received on exercise of warrants | 850,129 | - | ||||||
Payment of deferred offering costs | - | (155,260) | ||||||
Proceeds received from line of credit | - | 300,000 | ||||||
Repayments on line of credit | - | (751,952) | ||||||
Repayments on notes payable | (85,883) | - | ||||||
Proceeds received from convertible notes payable | - | 1,255,000 | ||||||
Net cash provided by financing activities | 764,246 | 647,788 | ||||||
NET CHANGE IN CASH AND CASH EQUIVALENTS | (42,118) | 593,067 | ||||||
CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIOD | 3,280,075 | 3,344 | ||||||
CASH AND CASH EQUIVALENTS AT END OF PERIOD | $ | 3,237,957 | $ | 596,411 | ||||
SUPPLEMENTAL INFORMATION: | ||||||||
Interest paid | $ | 4,077 | $ | 9,850 | ||||
Income taxes paid | $ | - | $ | - | ||||
| Last Trade: | US$0.94 |
| Daily Change: | -0.06 -5.86 |
| Daily Volume: | 138,116 |
| Market Cap: | US$6.220M |
August 08, 2024 July 30, 2024 May 14, 2024 | |
Amneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...
CLICK TO LEARN MORE
ClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...
CLICK TO LEARN MORE
